January 23, 2022

Morena Vista Trading Sues Emerging Pharmaceutical Company, Kinetana, for $6 Million for Intentional Misrepresentation and Breach of Contract

Morena Vista Trading LLC files suit against Kinetana International BioTech Pharma Limited in California State Superior Court seeking damages of $6 million for intentional misrepresentation, breach of contract, civil racketeering and corrupt organization claims. Kinetana is a pharmaceutical company publicly traded on the Growth Enterprise Exchange of the Hong Kong Stock Exchange with principal places of business in Edmonton, AB Canada and Hong Kong.

(PRWEB) January 23, 2022 -- Morena Vista Trading LLC filed suit this week against Kinetana International BioTech Pharma Ltd., a publicly traded company on the Growth Enterprise Market of the Hong Kong Stock Exchange/ Kinetana Holdings/ Kinetana Group Inc., of Edmonton, AB Canada/ it’s subsidiaries and key board members and shareholders, Dr. Yun K. Tam, Dr. Nuzhat Tam-Zaman and Mr. Sui Leung Yeung, in the California State Superior Court (case 04CC12637) seeking damages and relief of $6 million, while citing instances of intentional misrepresentation, breach of contract, civil racketeering and corrupt organization claims.

Morena Vista Trading (dba Kairos-Meade), a California based strategic business development & marketing company, formed a joint venture with Kinetana in April of 2004 to establish sales of Kinetana products in the U.S. and Canada.

Morena Vista Trading is seeking damages and relief in the amount of $6 million for intentional misrepresentation and breach of oral and written contracts resulting in loss of invested monies, business opportunities, unjust hardship due to willful misrepresentation and is requesting jury trial and constructive trust be imposed over the joint venture. Date of trial is pending.

Posted by Industrial at 07:55 AM | Comments (0)